Please ensure Javascript is enabled for purposes of website accessibility
Geron Stock Quote

Geron (NASDAQ: GERN)

$3.38
(2.4%)
$0.08
Price as of February 1, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geron Returns vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
GERN +194.64% +37.50% +6.58% -57%
S&P -9.72% +44.46% +7.63% +537%

Geron Company Info

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

News & Analysis

The Fool has written over 300 articles on Geron.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
401%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/01/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.